img

Global Bispecific Antibody Molecular Drug Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Bispecific Antibody Molecular Drug Market Research Report 2024

Bispecific antibody molecular drugs are developed on the basis of monoclonal antibodies and are regarded as the second-generation antibody therapy for tumor treatment. Bispecific antibody molecules do not exist in the natural state and can only be prepared artificially. Its development is through the co-expression of two different H chains and two different L chains. Therefore, bispecific antibodies can specifically bind 2 different antigens.
According to Mr Accuracy reports new survey, global Bispecific Antibody Molecular Drug market is projected to reach US$ 802.9 million in 2029, increasing from US$ 500 million in 2022, with the CAGR of 7.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Bispecific Antibody Molecular Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Bispecific Antibody Molecular Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


MacroGenics
Xencor
Medimmune
Merrimsck
Merus NV
Genentech
Zhongshan Kangfang Biology Medicine
Sichuan Baili Pharmaceutical
Alphamab Oncology
Amgen
Segment by Type
EGFR×HER3 Target
PD-1×CTLA-4 Target
HER2×HER3 Target

Segment by Application


Pancreatic Cancer
Breast Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
Solid Tumor
Others

Consumption by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Bispecific Antibody Molecular Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Bispecific Antibody Molecular Drug Market Overview
1.1 Product Overview and Scope of Bispecific Antibody Molecular Drug
1.2 Bispecific Antibody Molecular Drug Segment by Type
1.2.1 Global Bispecific Antibody Molecular Drug Market Value Comparison by Type (2024-2034)
1.2.2 EGFR×HER3 Target
1.2.3 PD-1×CTLA-4 Target
1.2.4 HER2×HER3 Target
1.3 Bispecific Antibody Molecular Drug Segment by Application
1.3.1 Global Bispecific Antibody Molecular Drug Market Value by Application: (2024-2034)
1.3.2 Pancreatic Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Non-Small Cell Lung Cancer
1.3.6 Solid Tumor
1.3.7 Others
1.4 Global Bispecific Antibody Molecular Drug Market Size Estimates and Forecasts
1.4.1 Global Bispecific Antibody Molecular Drug Revenue 2018-2029
1.4.2 Global Bispecific Antibody Molecular Drug Sales 2018-2029
1.4.3 Global Bispecific Antibody Molecular Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Bispecific Antibody Molecular Drug Market Competition by Manufacturers
2.1 Global Bispecific Antibody Molecular Drug Sales Market Share by Manufacturers (2018-2024)
2.2 Global Bispecific Antibody Molecular Drug Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Bispecific Antibody Molecular Drug Average Price by Manufacturers (2018-2024)
2.4 Global Bispecific Antibody Molecular Drug Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Bispecific Antibody Molecular Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bispecific Antibody Molecular Drug, Product Type & Application
2.7 Bispecific Antibody Molecular Drug Market Competitive Situation and Trends
2.7.1 Bispecific Antibody Molecular Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Bispecific Antibody Molecular Drug Players Market Share by Revenue
2.7.3 Global Bispecific Antibody Molecular Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Bispecific Antibody Molecular Drug Retrospective Market Scenario by Region
3.1 Global Bispecific Antibody Molecular Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Bispecific Antibody Molecular Drug Global Bispecific Antibody Molecular Drug Sales by Region: 2018-2029
3.2.1 Global Bispecific Antibody Molecular Drug Sales by Region: 2018-2024
3.2.2 Global Bispecific Antibody Molecular Drug Sales by Region: 2024-2029
3.3 Global Bispecific Antibody Molecular Drug Global Bispecific Antibody Molecular Drug Revenue by Region: 2018-2029
3.3.1 Global Bispecific Antibody Molecular Drug Revenue by Region: 2018-2024
3.3.2 Global Bispecific Antibody Molecular Drug Revenue by Region: 2024-2029
3.4 North America Bispecific Antibody Molecular Drug Market Facts & Figures by Country
3.4.1 North America Bispecific Antibody Molecular Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Bispecific Antibody Molecular Drug Sales by Country (2018-2029)
3.4.3 North America Bispecific Antibody Molecular Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bispecific Antibody Molecular Drug Market Facts & Figures by Country
3.5.1 Europe Bispecific Antibody Molecular Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Bispecific Antibody Molecular Drug Sales by Country (2018-2029)
3.5.3 Europe Bispecific Antibody Molecular Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bispecific Antibody Molecular Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Bispecific Antibody Molecular Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Bispecific Antibody Molecular Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Bispecific Antibody Molecular Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Bispecific Antibody Molecular Drug Market Facts & Figures by Country
3.7.1 Latin America Bispecific Antibody Molecular Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Bispecific Antibody Molecular Drug Sales by Country (2018-2029)
3.7.3 Latin America Bispecific Antibody Molecular Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Bispecific Antibody Molecular Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Bispecific Antibody Molecular Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Bispecific Antibody Molecular Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Bispecific Antibody Molecular Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bispecific Antibody Molecular Drug Sales by Type (2018-2029)
4.1.1 Global Bispecific Antibody Molecular Drug Sales by Type (2018-2024)
4.1.2 Global Bispecific Antibody Molecular Drug Sales by Type (2024-2029)
4.1.3 Global Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2029)
4.2 Global Bispecific Antibody Molecular Drug Revenue by Type (2018-2029)
4.2.1 Global Bispecific Antibody Molecular Drug Revenue by Type (2018-2024)
4.2.2 Global Bispecific Antibody Molecular Drug Revenue by Type (2024-2029)
4.2.3 Global Bispecific Antibody Molecular Drug Revenue Market Share by Type (2018-2029)
4.3 Global Bispecific Antibody Molecular Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Bispecific Antibody Molecular Drug Sales by Application (2018-2029)
5.1.1 Global Bispecific Antibody Molecular Drug Sales by Application (2018-2024)
5.1.2 Global Bispecific Antibody Molecular Drug Sales by Application (2024-2029)
5.1.3 Global Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2029)
5.2 Global Bispecific Antibody Molecular Drug Revenue by Application (2018-2029)
5.2.1 Global Bispecific Antibody Molecular Drug Revenue by Application (2018-2024)
5.2.2 Global Bispecific Antibody Molecular Drug Revenue by Application (2024-2029)
5.2.3 Global Bispecific Antibody Molecular Drug Revenue Market Share by Application (2018-2029)
5.3 Global Bispecific Antibody Molecular Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 MacroGenics
6.1.1 MacroGenics Corporation Information
6.1.2 MacroGenics Description and Business Overview
6.1.3 MacroGenics Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2024)
6.1.4 MacroGenics Bispecific Antibody Molecular Drug Product Portfolio
6.1.5 MacroGenics Recent Developments/Updates
6.2 Xencor
6.2.1 Xencor Corporation Information
6.2.2 Xencor Description and Business Overview
6.2.3 Xencor Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Xencor Bispecific Antibody Molecular Drug Product Portfolio
6.2.5 Xencor Recent Developments/Updates
6.3 Medimmune
6.3.1 Medimmune Corporation Information
6.3.2 Medimmune Description and Business Overview
6.3.3 Medimmune Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Medimmune Bispecific Antibody Molecular Drug Product Portfolio
6.3.5 Medimmune Recent Developments/Updates
6.4 Merrimsck
6.4.1 Merrimsck Corporation Information
6.4.2 Merrimsck Description and Business Overview
6.4.3 Merrimsck Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Merrimsck Bispecific Antibody Molecular Drug Product Portfolio
6.4.5 Merrimsck Recent Developments/Updates
6.5 Merus NV
6.5.1 Merus NV Corporation Information
6.5.2 Merus NV Description and Business Overview
6.5.3 Merus NV Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Merus NV Bispecific Antibody Molecular Drug Product Portfolio
6.5.5 Merus NV Recent Developments/Updates
6.6 Genentech
6.6.1 Genentech Corporation Information
6.6.2 Genentech Description and Business Overview
6.6.3 Genentech Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Genentech Bispecific Antibody Molecular Drug Product Portfolio
6.6.5 Genentech Recent Developments/Updates
6.7 Zhongshan Kangfang Biology Medicine
6.6.1 Zhongshan Kangfang Biology Medicine Corporation Information
6.6.2 Zhongshan Kangfang Biology Medicine Description and Business Overview
6.6.3 Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Product Portfolio
6.7.5 Zhongshan Kangfang Biology Medicine Recent Developments/Updates
6.8 Sichuan Baili Pharmaceutical
6.8.1 Sichuan Baili Pharmaceutical Corporation Information
6.8.2 Sichuan Baili Pharmaceutical Description and Business Overview
6.8.3 Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Product Portfolio
6.8.5 Sichuan Baili Pharmaceutical Recent Developments/Updates
6.9 Alphamab Oncology
6.9.1 Alphamab Oncology Corporation Information
6.9.2 Alphamab Oncology Description and Business Overview
6.9.3 Alphamab Oncology Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Alphamab Oncology Bispecific Antibody Molecular Drug Product Portfolio
6.9.5 Alphamab Oncology Recent Developments/Updates
6.10 Amgen
6.10.1 Amgen Corporation Information
6.10.2 Amgen Description and Business Overview
6.10.3 Amgen Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Amgen Bispecific Antibody Molecular Drug Product Portfolio
6.10.5 Amgen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bispecific Antibody Molecular Drug Industry Chain Analysis
7.2 Bispecific Antibody Molecular Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bispecific Antibody Molecular Drug Production Mode & Process
7.4 Bispecific Antibody Molecular Drug Sales and Marketing
7.4.1 Bispecific Antibody Molecular Drug Sales Channels
7.4.2 Bispecific Antibody Molecular Drug Distributors
7.5 Bispecific Antibody Molecular Drug Customers
8 Bispecific Antibody Molecular Drug Market Dynamics
8.1 Bispecific Antibody Molecular Drug Industry Trends
8.2 Bispecific Antibody Molecular Drug Market Drivers
8.3 Bispecific Antibody Molecular Drug Market Challenges
8.4 Bispecific Antibody Molecular Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Bispecific Antibody Molecular Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Bispecific Antibody Molecular Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Bispecific Antibody Molecular Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Bispecific Antibody Molecular Drug Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Bispecific Antibody Molecular Drug Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Bispecific Antibody Molecular Drug Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Bispecific Antibody Molecular Drug Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Bispecific Antibody Molecular Drug Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Bispecific Antibody Molecular Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Bispecific Antibody Molecular Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Bispecific Antibody Molecular Drug, Product Type & Application
Table 12. Global Key Manufacturers of Bispecific Antibody Molecular Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Bispecific Antibody Molecular Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bispecific Antibody Molecular Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Bispecific Antibody Molecular Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Bispecific Antibody Molecular Drug Sales by Region (2018-2024) & (K Units)
Table 18. Global Bispecific Antibody Molecular Drug Sales Market Share by Region (2018-2024)
Table 19. Global Bispecific Antibody Molecular Drug Sales by Region (2024-2029) & (K Units)
Table 20. Global Bispecific Antibody Molecular Drug Sales Market Share by Region (2024-2029)
Table 21. Global Bispecific Antibody Molecular Drug Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Bispecific Antibody Molecular Drug Revenue Market Share by Region (2018-2024)
Table 23. Global Bispecific Antibody Molecular Drug Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Bispecific Antibody Molecular Drug Revenue Market Share by Region (2024-2029)
Table 25. North America Bispecific Antibody Molecular Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Bispecific Antibody Molecular Drug Sales by Country (2018-2024) & (K Units)
Table 27. North America Bispecific Antibody Molecular Drug Sales by Country (2024-2029) & (K Units)
Table 28. North America Bispecific Antibody Molecular Drug Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Bispecific Antibody Molecular Drug Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Bispecific Antibody Molecular Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Bispecific Antibody Molecular Drug Sales by Country (2018-2024) & (K Units)
Table 32. Europe Bispecific Antibody Molecular Drug Sales by Country (2024-2029) & (K Units)
Table 33. Europe Bispecific Antibody Molecular Drug Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Bispecific Antibody Molecular Drug Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Bispecific Antibody Molecular Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Bispecific Antibody Molecular Drug Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Bispecific Antibody Molecular Drug Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Bispecific Antibody Molecular Drug Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Bispecific Antibody Molecular Drug Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Bispecific Antibody Molecular Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Bispecific Antibody Molecular Drug Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Bispecific Antibody Molecular Drug Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Bispecific Antibody Molecular Drug Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Bispecific Antibody Molecular Drug Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Bispecific Antibody Molecular Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Bispecific Antibody Molecular Drug Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Bispecific Antibody Molecular Drug Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Bispecific Antibody Molecular Drug Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Bispecific Antibody Molecular Drug Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Bispecific Antibody Molecular Drug Sales (K Units) by Type (2018-2024)
Table 51. Global Bispecific Antibody Molecular Drug Sales (K Units) by Type (2024-2029)
Table 52. Global Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2024)
Table 53. Global Bispecific Antibody Molecular Drug Sales Market Share by Type (2024-2029)
Table 54. Global Bispecific Antibody Molecular Drug Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Bispecific Antibody Molecular Drug Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Bispecific Antibody Molecular Drug Revenue Market Share by Type (2018-2024)
Table 57. Global Bispecific Antibody Molecular Drug Revenue Market Share by Type (2024-2029)
Table 58. Global Bispecific Antibody Molecular Drug Price (US$/Unit) by Type (2018-2024)
Table 59. Global Bispecific Antibody Molecular Drug Price (US$/Unit) by Type (2024-2029)
Table 60. Global Bispecific Antibody Molecular Drug Sales (K Units) by Application (2018-2024)
Table 61. Global Bispecific Antibody Molecular Drug Sales (K Units) by Application (2024-2029)
Table 62. Global Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2024)
Table 63. Global Bispecific Antibody Molecular Drug Sales Market Share by Application (2024-2029)
Table 64. Global Bispecific Antibody Molecular Drug Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Bispecific Antibody Molecular Drug Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Bispecific Antibody Molecular Drug Revenue Market Share by Application (2018-2024)
Table 67. Global Bispecific Antibody Molecular Drug Revenue Market Share by Application (2024-2029)
Table 68. Global Bispecific Antibody Molecular Drug Price (US$/Unit) by Application (2018-2024)
Table 69. Global Bispecific Antibody Molecular Drug Price (US$/Unit) by Application (2024-2029)
Table 70. MacroGenics Corporation Information
Table 71. MacroGenics Description and Business Overview
Table 72. MacroGenics Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. MacroGenics Bispecific Antibody Molecular Drug Product
Table 74. MacroGenics Recent Developments/Updates
Table 75. Xencor Corporation Information
Table 76. Xencor Description and Business Overview
Table 77. Xencor Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. Xencor Bispecific Antibody Molecular Drug Product
Table 79. Xencor Recent Developments/Updates
Table 80. Medimmune Corporation Information
Table 81. Medimmune Description and Business Overview
Table 82. Medimmune Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Medimmune Bispecific Antibody Molecular Drug Product
Table 84. Medimmune Recent Developments/Updates
Table 85. Merrimsck Corporation Information
Table 86. Merrimsck Description and Business Overview
Table 87. Merrimsck Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. Merrimsck Bispecific Antibody Molecular Drug Product
Table 89. Merrimsck Recent Developments/Updates
Table 90. Merus NV Corporation Information
Table 91. Merus NV Description and Business Overview
Table 92. Merus NV Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. Merus NV Bispecific Antibody Molecular Drug Product
Table 94. Merus NV Recent Developments/Updates
Table 95. Genentech Corporation Information
Table 96. Genentech Description and Business Overview
Table 97. Genentech Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. Genentech Bispecific Antibody Molecular Drug Product
Table 99. Genentech Recent Developments/Updates
Table 100. Zhongshan Kangfang Biology Medicine Corporation Information
Table 101. Zhongshan Kangfang Biology Medicine Description and Business Overview
Table 102. Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Product
Table 104. Zhongshan Kangfang Biology Medicine Recent Developments/Updates
Table 105. Sichuan Baili Pharmaceutical Corporation Information
Table 106. Sichuan Baili Pharmaceutical Description and Business Overview
Table 107. Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Product
Table 109. Sichuan Baili Pharmaceutical Recent Developments/Updates
Table 110. Alphamab Oncology Corporation Information
Table 111. Alphamab Oncology Description and Business Overview
Table 112. Alphamab Oncology Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. Alphamab Oncology Bispecific Antibody Molecular Drug Product
Table 114. Alphamab Oncology Recent Developments/Updates
Table 115. Amgen Corporation Information
Table 116. Amgen Description and Business Overview
Table 117. Amgen Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. Amgen Bispecific Antibody Molecular Drug Product
Table 119. Amgen Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Bispecific Antibody Molecular Drug Distributors List
Table 123. Bispecific Antibody Molecular Drug Customers List
Table 124. Bispecific Antibody Molecular Drug Market Trends
Table 125. Bispecific Antibody Molecular Drug Market Drivers
Table 126. Bispecific Antibody Molecular Drug Market Challenges
Table 127. Bispecific Antibody Molecular Drug Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Bispecific Antibody Molecular Drug
Figure 2. Global Bispecific Antibody Molecular Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Bispecific Antibody Molecular Drug Market Share by Type in 2022 & 2029
Figure 4. EGFR×HER3 Target Product Picture
Figure 5. PD-1×CTLA-4 Target Product Picture
Figure 6. HER2×HER3 Target Product Picture
Figure 7. Global Bispecific Antibody Molecular Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 8. Global Bispecific Antibody Molecular Drug Market Share by Application in 2022 & 2029
Figure 9. Pancreatic Cancer
Figure 10. Breast Cancer
Figure 11. Colorectal Cancer
Figure 12. Non-Small Cell Lung Cancer
Figure 13. Solid Tumor
Figure 14. Others
Figure 15. Global Bispecific Antibody Molecular Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Bispecific Antibody Molecular Drug Market Size (2018-2029) & (US$ Million)
Figure 17. Global Bispecific Antibody Molecular Drug Sales (2018-2029) & (K Units)
Figure 18. Global Bispecific Antibody Molecular Drug Average Price (US$/Unit) & (2018-2029)
Figure 19. Bispecific Antibody Molecular Drug Report Years Considered
Figure 20. Bispecific Antibody Molecular Drug Sales Share by Manufacturers in 2022
Figure 21. Global Bispecific Antibody Molecular Drug Revenue Share by Manufacturers in 2022
Figure 22. The Global 5 and 10 Largest Bispecific Antibody Molecular Drug Players: Market Share by Revenue in 2022
Figure 23. Bispecific Antibody Molecular Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 24. Global Bispecific Antibody Molecular Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 25. North America Bispecific Antibody Molecular Drug Sales Market Share by Country (2018-2029)
Figure 26. North America Bispecific Antibody Molecular Drug Revenue Market Share by Country (2018-2029)
Figure 27. United States Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Canada Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Europe Bispecific Antibody Molecular Drug Sales Market Share by Country (2018-2029)
Figure 30. Europe Bispecific Antibody Molecular Drug Revenue Market Share by Country (2018-2029)
Figure 31. Germany Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. France Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. U.K. Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Italy Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Russia Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Asia Pacific Bispecific Antibody Molecular Drug Sales Market Share by Region (2018-2029)
Figure 37. Asia Pacific Bispecific Antibody Molecular Drug Revenue Market Share by Region (2018-2029)
Figure 38. China Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Japan Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. South Korea Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. India Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Australia Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. China Taiwan Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Southeast Asia Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Latin America Bispecific Antibody Molecular Drug Sales Market Share by Country (2018-2029)
Figure 46. Latin America Bispecific Antibody Molecular Drug Revenue Market Share by Country (2018-2029)
Figure 47. Mexico Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Brazil Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Argentina Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Bispecific Antibody Molecular Drug Sales Market Share by Country (2018-2029)
Figure 51. Middle East & Africa Bispecific Antibody Molecular Drug Revenue Market Share by Country (2018-2029)
Figure 52. Turkey Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. UAE Bispecific Antibody Molecular Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Global Sales Market Share of Bispecific Antibody Molecular Drug by Type (2018-2029)
Figure 56. Global Revenue Market Share of Bispecific Antibody Molecular Drug by Type (2018-2029)
Figure 57. Global Bispecific Antibody Molecular Drug Price (US$/Unit) by Type (2018-2029)
Figure 58. Global Sales Market Share of Bispecific Antibody Molecular Drug by Application (2018-2029)
Figure 59. Global Revenue Market Share of Bispecific Antibody Molecular Drug by Application (2018-2029)
Figure 60. Global Bispecific Antibody Molecular Drug Price (US$/Unit) by Application (2018-2029)
Figure 61. Bispecific Antibody Molecular Drug Value Chain
Figure 62. Bispecific Antibody Molecular Drug Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed